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Abstract 
Introduction 
• Atrial fibrillation is the most common sustained heart 
rhythm in the United States 
• Largest risk for patients with atrial fibrillation is that of 
ischemic stroke from embolization of an atrial clot. 
• Many food-drug and drug-drug interactions that can 
greatly influence the pharmacodynamics of warfarin 
leading to an extremely variable dose response curve, 
and a constant need for laboratory monitoring to ensure 
adequate anticoagulation 
• Several large, phase III, randomized controlled trials that 
have investigated the safety and efficacy of these newer 
anticoagulants compared to traditional warfarin therapy 
Research Questions 
Literature Review 
Applicability to Clinical 
Practice 
Special thanks  
Discussion 
• Currently no laboratory test to monitor the 
effects of any novel anticoagulant.  
• In patients with renal insufficiency, half life of 
drug is lengthened  
• No antidote to counteract the effects of direct 
thrombin or factor Xa inhibitors. 
• All authors indicated the need for an adequately 
powered head to head study of direct thrombin 
inhibitors versus factor Xa inhibitors. 
• Current literature indicates cost effectiveness 
but still many more questions than answers. 
Atrial fibrillation is the most common sustained heart rhythm 
in the United States with estimated prevalence rates of 
8.8/100 (Wolf, Abbott, & Kannel, 1991).  The largest risk 
for patients with atrial fibrillation is that of ischemic stroke 
from embolization of an atrial clot, thus the long standing 
treatment for this arrhythmia is aggressive anticoagulation. 
For decades this has been accomplished with the use of 
warfarin, however, the increased risk of hemorrhage 
combined with the inconvenience of weekly blood testing 
has prompted the development of potentially safer and 
more effective alternatives. A systematic review of the 
literature identified studies that examined the safety and 
efficacy of direct thrombin and factor Xa inhibitors 
compared with traditional warfarin therapy. It was found 
that the new anticoagulants reduce the incidence of stroke 
and thromboembolism without increasing the risk of major 
hemorrhage when compared to warfarin. This provides 
health care providers another option to safely anti-
coagulate patients diagnosed with non-valvular atrial 
fibrillation without the burden of PT/INR monitoring. 
 
• In patients with non-valvular atrial fibrillation, are the novel, 
oral anticoagulants a safer and more effective option for 
the prevention of stroke and systemic  embolism? 
• In patients that are anticoagulated with any novel 
anticoagulant, is there a reversal agent available in the 
event of major trauma, bleeding, or the need for surgery? 
• Are novel anticoagulants a cost effective option compared 
to warfarin in patients with non-valvular atrial fibrillation? 
 
• Primary end point of stroke or systemic embolism was 
lower with novel anticoagulants compared with warfarin 
• Risk of death from any cause was lower with all novel 
anticoagulants than with warfarin 
• Significant reduction in hemorrhagic stroke with novel 
anticoagulants compared to warfarin 
• The issues of cost, safety, and efficacy must be continually 
investigated by researchers and evaluated by providers in 
order to optimize outcomes for any patients requiring 
anticoagulation. 
• The use of any novel anticoagulant or warfarin is clearly 
better than the avoidance of any anticoagulation in 
patients with atrial fibrillation 
• Consideration should be given to individual patients stroke 
and bleeding risk factors, potential financial burden, 
desired clinical effect, and patient/family concerns prior to 
initiation or alteration of anticoagulation. 
A sincere thank you to Sue Kuntz who served as the faculty 
advisor and mentor for this project; Jeanie McHugo and Jay 
Metzger for their constant professionalism and commitment 
to excellence in all facets of the University of North Dakota 
physician assistant program; Michael Robertson, M.D. for 
his role as primary clinical preceptor, mentor, and friend; and 
my wife Erin, for her patience, love, and continuous support 
of my return to further my education. 
 
Statement of the Problem 
• Warfarin has long been recognized as an effective 
therapy to prevent the occurrence of stroke and systemic 
embolism; however, the risk for bleeding, the variable 
dose-response curve, and the inconvenience of routine 
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Study Drug No. of Patients Masking Test Analysis (Primary Outcome) Follow-up mo.
RE-LY Dabigatran 12098 Open label Noninferiority ITT 300
ROCKET AF Rivaroxaban 14264 Double blind Noninferiority ITT 20
ARISTOTLE Apixaban 18201 Double blind Noninferiority ITT 10
Abbreviations: ARISTOTLE, Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation; ITT, intention to treat; RE-LY, Randomized 
Evaluation of Long-Term Anticoagulant Therapy; ROCKET AF, An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of 
Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation. a RE-LY trial included 18113 patients; 
there were 6015 patients excluded because they belonged to the low-dose study branch.
Table 1. Main Study Characteristics
Dabigatran Warfarin Rivaroxaban Warfarin Apixaban Warfarin
Male (%) 63.2 63.2 60.3 60.3 60.5 65
Age (y) 71.5 71.6 73 73 70 70
Aspirin at entry (%) 38.7 40.6 36.3 36.3 31.3 30.5
Vitamin K antagonist at entry (%) 62.3 62.5
Long-term vitamin K antagonist therapy (%) 50.2 48.6 57.1 57.2
Risk factors for stroke ≥3 (%) 32.6 32.1 87 86.9 30.2 30.2
Previous  stroke, TIA, or both (%) 20.3 19.8
Previous stroke, TIA, or embolism (%) 54.9 54.6 19.2 19.7
Hypertension (%) 78.9 78.9 90.3 90.8 87.3 87.6
Diabetes (%) 23.1 23.4 40.4 39.5 25 24.9
LVD or heart failure (%) 31.8 31.9 62.6 62.6 35.5 35.4
Table 2. Baseline Characteristics of the Patients
RE-LY ROCKET AF ARISTOTLE
Abbreviations: ARISTOTLE, Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation; LVD, left ventricular 
dysfunction; RE-LY, Randomized Evaluation of Long-Term Anticoagulant Therapy; ROCKET AF, An Efficacy and Safety Study of 
Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients with Non-
Valvular Atrial Fibrillation; TIA, transient ischemic accident
Characteristics
